

The Medicare prescription drug program (Part D): Status report

Rachel Schmidt and Shinobu Suzuki January 11, 2018



Overview of the presentation

- Program description and key trends
- Plan strategies to manage Part D premiums
- Growth in drug prices
- Trends in program spending
- Draft recommendation




Snapshot of the Part D program

- Among 58.6 million Medicare beneficiaries in 2017:
 - 42.5 million (72.5%) enrolled in Part D plans
 - Another 2.7% received retiree drug subsidy (RDS)
 - 24.8% had coverage as generous through other sources, had no coverage, or had less generous coverage
- Program spending of nearly \$80 billion in 2016
 - Nearly \$79 billion for payments to Part D plans
 - About \$1 billion for RDS
- Plan enrollees
 - Paid nearly \$13 billion in premiums (excluding Medicare premium subsidies for low-income enrollees) plus additional amounts in cost sharing
 - Most continue to say they are satisfied

Part D's coverage gap is closing, but brand manufacturer discount will remain


Defined standard benefit in 2018 Plan Enrollee 5% -Medicare 80% 15% **OOP** threshold ~\$8,400 Coverage gap Initial coverage limit \$3,750 Enrollee Plan 75% 25% Enrollee 100% Deductible \$405

MECIDAC



Brand-name drugs in gap

Generics / biosimilars in gap



□ Plan ■ Enrollee

Part D enrollment in 2017 and plan offerings for 2018

Enrollment in 2017

- 59% of all Part D enrollees in PDPs, 41% in MA-PDs (compared with 70% in PDPs, 30% in MA-PDs in 2007)
- 29% of all Part D enrollees receive LIS (down from 39% in 2007)
- 36% of LIS enrollees in MA-PDs (up from 14% in 2007)

Plan offerings for 2018

- 16% more MA-PDs
- 5% more PDPs, range of 19 26 per region
- 6% decrease in PDPs qualifying as premium-free to LIS enrollees; one region has 2 qualifying PDPs, the rest have 3 – 10 per region



Key trends since start of Part D

Enrollment growth

- 24 million in 2007 to 42.5 million in 2017 (6% per year)
- Higher among non-LIS enrollees (7%) than LIS (3%)
- Move from RDS to Part D employer-group plans
- Average monthly premiums, 2010 to 2017
 - Stable average at \$30 \$32 per month, but wide variation
 - Faster growth in MA-PD premiums (4%) than PDP premiums (1%)
- Per capita Medicare reinsurance payments to plans have grown much faster than enrollee premiums
 - 7% per year, 2007 2010
 - 13% per year, 2010 2016




Strategies to manage Part D premiums

Formulary design

- Typically 5-tier formularies
- Within limits, trend toward moderate tightening
- Manufacturer rebates
 - Grown from <10% of gross Part D spending in 2007 to approximately 22% in 2016
 - Use of "price-protection" rebates
- Pharmacy networks
 - Preferred cost-sharing pharmacies
 - Pharmacy fees growing
- Specialty pharmacies

медрас

Growth in brand prices more than offsets effects of generic use





Source: Acumen, LLC for MedPAC based on Part D prescription drug event data. Note: Indexes do not reflect rebates from manufacturers. Results are preliminary and subject to change.

Cost-based reimbursement has grown as a share of basic benefit costs


Spending category	Spending in billions		Percentage growth		
	2007	2016	Cumulative	Average annual	
Direct subsidy*	\$17.6	\$16.3	-7.4%	-0.8%	
Reinsurance	<u>8.0</u>	<u>34.8</u>	<u>335.0%</u>	<u>17.7%</u>	
Subtotal, basic benefits	25.6	51.1	99.6%	8.0%	
Low-income subsidy	16.7	26.7	59.9%	5.4%	
Retiree drug subsidy	<u>3.9</u>	<u>1.1</u>	<u>-71.8%</u>	<u>-13.1%</u>	
Medicare program total	46.2	78.9	70.8%	6.1%	



Source: MedPAC based on Table IV.B.10 of the Medicare Board of Trustees' report for 2017. Note: Results are preliminary and subject to change. RDS (retiree drug subsidy). * Net of Part D risk-corridor payments.

Nearly all of the growth in spending for high-cost enrollees is due to higher prices

Components of annual average growth in spending, 2010-2015



In 2015,

- 8% of Part D enrollees reached the catastrophic phase (high-cost enrollees)
- High-cost enrollees accounted for 57% of overall spending
- Use of higher-priced drugs will continue to put strong upward pressure on program spending

медрас

Source: MedPAC analysis of Part D prescription drug event data. Note: Results are preliminary and subject to change. "High-cost enrollees" are beneficiaries who reach Part D's out-ofpocket threshold. Price reflects inflation and changes in mix of drugs used.

Many factors driving more catastrophic spending

- Growth in enrollment, especially non-LIS
- Higher drug prices
- Coverage gap discount
- Plan incentives to put high-price, high-rebate drugs on formularies
- →More high-cost enrollees
- Rapid growth in Medicare's payments for reinsurance

Trend likely to continue because of increasing focus on specialty drugs and biologics in the pipeline MEC/DAC

The Commission's June 2016 Part D recommendations

Change Part D to:

- Transition Medicare's reinsurance from 80% to 20% of catastrophic spending and keep Medicare's overall subsidy at 74.5% through higher capitated payments
- Exclude manufacturers' discounts in the coverage gap from enrollees' "true OOP" spending
- Eliminate cost sharing above the OOP threshold
- Make moderate changes to LIS cost sharing to encourage use of generics and biosimilars
- Greater flexibility to use formulary tools



Need to remove financial disincentive to use biosimilars

Biologics will continue to grow in importance

- Increasing cost burden on patients and Medicare
- Need for biosimilars to promote price competition
- <u>BUT</u> some Part D policies may negatively affect take up of biosimilars
 - Copays for LIS enrollees
 - Coverage-gap discount provides financial advantage to originator biologics over biosimilars

